ArticleCurrent breast cancer reports2010
PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
Article in Current breast cancer reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers.Frontiers in oncology · 2022Pooled it
- Insights from three decades of BRCA1/2 modeling in mice.Nature genetics · 2026Review
- Role of Poly (ADP-Ribose) Polymerase-1 (PARP1) and Its Inhibitors for Cancer Therapy.Mini reviews in medicinal chemistry · 2026Review
- Promises and pitfalls of multi-cancer early detection using liquid biopsy tests.Nature reviews. Clinical oncology · 2025Review
- The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments - parallels with other neurodegenerative disorders.Frontiers in pharmacology · 2025Review
- Contraception as chemoprevention of ovarian cancer in BRCA1 and BRCA2 women.Hormones (Athens, Greece) · 2024Review
- Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.Frontiers in oncology · 2024Review
- Biochemical, Structural Analysis, and Docking Studies of Spiropyrazoline Derivatives.International journal of molecular sciences · 2022Article
- PARkinson's: From cellular mechanisms to potential therapeutics.Pharmacology & therapeutics · 2022Review
- Targeting DNA Repair Pathways in Hematological Malignancies.International journal of molecular sciences · 2020Review
- Multi gene panel testing for hereditary breast cancer - is it ready to be used?Medicine and pharmacy reports · 2019Review
- Article
- Emerging strategies in BRCA-positive pancreatic cancer.Journal of cancer research and clinical oncology · 2018Review
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.Nature reviews. Molecular cell biology · 2017Review
- Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics.Annual review of pharmacology and toxicology · 2017Review
- DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.NPJ breast cancer · 2017Article
- Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.Cancer research · 2014Article
- The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.Breast cancer research and treatment · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Poly (ADP-ribose) polymerase (PARP) inhibitors, a novel class of drugs that target tumors with DNA repair defects, have received tremendous enthusiasm. Early preclinical studies identified BRCA1 and BRCA2 tumors to be highly sensitive to PARP inhibitors as a result of homologous recombination defect. Based on this premise, PARP inhibitors have been tested in early phase clinical trials as a single agent in BRCA1 or BRCA2 mutation carriers and in combination with chemotherapy in triple-negative breast cancer patients. For high-risk populations, use of PARP inhibition as a prevention agent has been postulated, but no robust preclinical or clinical studies exist yet. We review the preclinical and clinical studies in treatment of breast cancer and rationale for use of PARP inhibitors as a prevention agent for high-risk populations. Of significance, PARP inhibitors vary significantly in mechanism of action, dosing intervals, and toxicities, which are highlighted in this review.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.